Why the study?
Data regarding whether concomitant mineralocorticoid receptor antagonist usage influences the efficacy of SGLT2 inhibitors on clinical endpoints in patients with heart failure are ambiguous.
Meta-Analysis
Answers are grounded in this paper and cite their sources.
Baseline MRA effect on SGLT2 inhibitor efficacy in HF remains unquantified; full results needed to clarify interaction.
Mineralocorticoid receptor antagonists (MRAs) are considered part of the cornerstone of treatment in patients with heart failure (HF).1 The European Society of Cardiology guidelines for the management of HF have given class Ia recommendations for the utilization of MRAs in patients with HF with reduced ejection fraction (HFrEF).2 However, MRAs remain underused in clinical practice due to their risk of precipitating hyperkalemia and worsening renal function.1 More recently, sodium-glucose cotransporter-2 inhibitors (SGLT2is) have shown beneficial effects in patients with HF across broad range of ejection fraction.3–8 Although the combined diuretic action of these two drugs may carry the risk of volume depletion and hypotension, the potential benefits of concomitant administration of MRAs and SGLT2is on clinical outcomes may outweigh safety concerns. Data regarding whether concomitant MRA usage influences the efficacy of SGLT2is on clinical endpoints in patients with HF are ambiguous. Therefore, we conducted a meta-analysis...
No takes yet. Share an insight, caveat, or question.
Arshad et al. (2022) conducted a meta-analysis in Heart failure. Sodium-glucose cotransporter-2 inhibitors (SGLT2is) stratified by baseline MRA use was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: